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Background: Indicated primary prevention in young people at Clinical High Risk for 
Psychosis (CHR-P) is a promising avenue for improving outcomes of one of the most 
severe mental disorders but their effectiveness has recently been questioned.
Methods: Umbrella review. A multi-step independent literature search of Web of Science 
until January 11, 2019, identified interventional meta-analyses in CHR-P individuals. The 
individual randomised controlled trials that were analysed by the meta-analyses were 
extracted. A review of ongoing trials and a simulation of living meta-analysis complemented 
the analysis.
Results: Seven meta-analyses investigating preventive treatments in CHR-P individuals 
were included. None of them produced pooled effect sizes across psychological, 
pharmacological, or other types of interventions. The outcomes analysed encompassed 
risk of psychosis onset, the acceptability of treatments, the severity of attenuated 
positive/negative psychotic symptoms, depression, symptom-related distress, social 
functioning, general functioning, and quality of life. These meta-analyses were based on 
20 randomised controlled trials: the vast majority defined the prevention of psychosis 
onset as their primary outcome of interest and only powered to large effect sizes. There 
was no evidence to favour any preventive intervention over any other (or control condition) 
for improving any of these clinical outcomes. Caution is required when making clinical 
recommendations for the prevention of psychosis in individuals at risk.
Discussion: Prevention of psychosis from a CHR-P state has been, and should remain, 
the primary outcome of interventional research, refined and complemented by other 
clinically meaningful outcomes. Stagnation of knowledge should promote innovative 
and collaborative research efforts, in line with the progressive and incremental nature of 
medical knowledge. Advancements will most likely be associated with the development 
of new experimental therapeutics that are ongoing along with the ability to deconstruct 
the high heterogeneity within CHR-P populations. This would require the estimation of 
treatment-specific effect sizes through living individual participant data meta-analyses, 
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controlling risk enrichment during recruitment, statistical power, and embedding precision 
medicine within youth mental health services that can accommodate sequential prognosis 
and advanced trial designs.
conclusions: The evidence-based challenges and proposed solutions addressed by 
this umbrella review can inform the next generation of research into preventive treatments 
for psychosis.
Keywords: psychosis, schizophrenia, prevention, treatments, meta-analysis, evidence
iNTRODUcTiON
Prevention of psychosis is a promising avenue for improving 
outcomes of one of the most severe mental disorders (1). It 
entails three stepped core components: efficient detection of 
individuals at risk, an accurate prognosis of outcomes, and an 
effective preventive treatment that can impact the course of the 
disorder (2). These activities are usually managed by specialised 
clinical services. The first rate-limiting step is the detection of 
children, adolescents and young adults aged 8–40 (3) (more 
frequently 14–35) (4) who may be at risk of developing psychosis. 
Their detection is based on recruitment campaigns (5) that filter 
individuals who have accumulated several risk factors (6) for 
the development of psychosis, thus enriching the level of risk. 
The second step is the clinical assessment of these individuals 
and the formulation of a prognosis (7–9). Individuals meeting 
psychometric intake criteria for a Clinical High Risk state for 
Psychosis (CHR-P (10)) are functionally impaired (11) and 
have a 20% risk of developing psychosis at 2 years (12)] [but 
not an increased risk of developing other non-psychotic mental 
disorders (13, 14)]. The third, final step is the provision of an 
effective intervention, which can impact the clinical outcomes of 
CHR-P individuals. Evidence of effective interventions in CHR-P 
individuals—also termed as primary indicated interventions 
(15)—will be the focus of the current manuscript.
We first review the historical development of preventive 
treatments for psychosis by adapting the “Gartner Hype Cycle 
(16)” model to the CHR-P paradigm [for details, see (17)]. The 
Hype Cycle has been used to describe the course of knowledge in 
other areas of medical knowledge [e.g., machine-learning (18)]. 
The Gartner Hype Cycle describes the course of new technological 
discoveries, assuming that humans tend to overestimate the impact 
of a new discovery in the short term, while largely underestimating 
the same in the long term. The Hype Cycle—illustrated in 
Figure 1—includes five different stages: 1) innovative trigger, 2) 
peak of inflated expectations, 3) trough of disillusionment, 4) slope 
of enlightenment, and 5) plateau of productivity or knowledge.
With reference to the CHR-P paradigm, the innovative trigger 
for the development of preventive treatments for psychosis was 
the set-up of the first CHR-P clinic (in 1995), followed (in 2002) by 
the publication of the first randomised controlled trial in CHR-P 
individuals. Such a trial employed antipsychotic (risperidone) 
and psychological treatment, and demonstrated that they were 
effective in reducing the risk of developing a first episode of 
psychosis in CHR-P samples (19). Over the ensuing years, the 
innovative trigger led to an explosion of enthusiasm with the 
development of additional treatments that—it was hoped—could 
prevent the onset of psychosis from a CHR-P state. Randomised 
controlled trials involving antipsychotics [olanzapine, 2006 (20), 
psychological therapies [Cognitive Behavioural Therapy (21), 
2004 or Integrated Psychological Intervention (22), 2012] and 
dietary interventions [Omega-3 (23)] all confirmed some degree of 
efficacy for reducing the onset of psychosis in CHR-P individuals 
(Figure 1). The peak of inflated expectations and optimism was 
likely reached through the publication of the National Institute 
for Health and Care Excellence (NICE) Clinical Guidelines 178 
(2014) (24) and the European Psychiatric Association (EPA) 
guidelines [2015 (25)] These guidelines set the gold standard 
for the prevention of psychosis in CHR-P individuals in clinical 
routine. At the same time, these guidelines also represented the 
starting point of the trough of disillusionment, because they were 
grounded on “non-conclusive (26)” and “moderate quality (26)” 
evidence of small magnitude (risk difference −0.07: 95%CIs −0.14 
to −0.01) (26). Upon closer inspection, the two guidelines were 
already reflecting a lack of robust evidence at the time of their 
release, because they were partially discordant. In fact, while 
prophylactic treatment with antipsychotics was altogether not 
recommended by NICE guidelines (24), the EPA allowed their use 
in the case of severe and progressive symptomatology (24). Over 
the following years, the trough of disillusionment for effective 
preventive treatments for psychosis onset received additional 
corroborating support. Two large randomized controlled trials 
showed that neither cognitive behavioral therapy [2012 (27)] 
nor Omega-3 interventions [2017/2018 (28, 29)] are effective 
in reducing the progression to psychosis from a CHR-P state. 
Overall, seven new trials involving 992 new CHR-P participants 
(an increase of more than 50%) have been published since the last 
meta-analysis that informed the NICE guidelines (30). All of these 
trials were negative (30, 31). An updated network meta-analysis 
(2018) (30) incorporating these new randomized controlled trials 
confirmed the lack of evidence to support specific preventive 
treatments over each—and every—other for the prevention of 
psychosis in CHR-P individuals.
The current trough of disillusionment phase has stimulated 
discussion across the field. On the one hand, some authors have 
attempted to minimize the clinical relevance of the evidence 
itself. Specifically, it has been argued that current preventive 
treatments are actually effective on outcomes other than the 
prevention of psychosis onset, that recent network meta-analyses 
should have estimated effects across different types of preventive 
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treatments “pooled together”, and that the primary outcome 
analysed by these meta-analyses—i.e., transition to psychosis 
from a CHR-P state—is a “second-order issue” of questionable 
clinical significance (32). On the other side, some authors have 
argued that there is now enough evidence to abandon the CHR-P 
paradigm altogether. The current study explores the area between 
these two polarities, to recognize the key challenges while at the 
same time proposing ways to overcome them. To address such an 
uncertain phase of knowledge, we strictly adopt an evidence-based 
medicine approach. We will interrogate the published literature 
by conducting an umbrella review (33), i.e., a review of meta-
analyses in the field of preventive interventions for psychosis in 
CHR-P individuals. Because umbrella reviews are based on meta-
analyses previously published, they represent a bird’s-eye view on a 
determinate topic and reflect one of the highest levels of evidence. 
First, we will specifically review the evidence that preventive 
interventions can impact clinical outcomes (including and going 
beyond the development of psychosis) in CHR-P individuals. 
We will also review the use of pooled vs treatment-specific effect 
size estimates. Second, we will systematically review the extent to 
which prevention of psychosis has been the first or second-order 
outcome in interventional studies in this population. Third, we 
will critically interpret the umbrella review findings to inform the 
next slope of enlightenment stage, which will hopefully deliver a 
plateau of knowledge in this field.
METHODS
Search Strategy, Selection criteria, and 
Data Extraction for the Systematic Review
A multi-step literature search was performed. First, systematic 
searches were conducted in the Web of Science (which includes 
Web of Science Core Collection, BIOSIS Citation Index, KCI—
Korean Journal Database, MEDLINE, Russian Science Citation 
Index, and SciELO Citation Index), until January 11, 2019, with 
no restrictions on language or publication date. The keywords 
“psychosis risk” or “clinical high risk” or “at risk mental state” 
or “prodromal,” “CAARMS” or “SIPS” or “basic symptoms” or 
“UHR” or “CHR” were used, filtering for the category “review” 
and “psychiatry” through the Web of Science categories function. 
Second, we searched the abstracts of retrieved articles to include 
only those that employed meta-analytical methods. Third, full-
text articles identified by this process were then screened and 
inspected against the inclusion and exclusion criteria.
The literature search, study selection, and data extraction were 
conducted by two authors independently. During all stages, in 
the case of disagreement, the consensus was reached through 
discussion with a third author.
Studies were eligible for inclusion when the following criteria 
were fulfilled: a) meta-analyses (aggregate or network) in CHR-P 
individuals [defined according to established international 
criteria (3)]; b) a clear and primary focus on interventions 
for this patient population, with no restriction on the design 
of the primary studies (open-label, controlled/uncontrolled, 
randomised/unrandomized, naturalistic studies) or on the 
type of the intervention (medications, psychological, physical, 
dietary, experimental); c) investigating clinical outcomes in 
CHR-P individuals. The exclusion criteria were: a) original 
studies, study protocols, abstracts, systematic reviews without 
quantitative analyses, and any other non-meta-analytical study; 
and b) lacking a clear primary focus on interventions for CHR 
individuals. In the case of two or more articles addressing the 
same outcome we selected individual participant data meta-
analyses over aggregate network meta-analyses over pairwise-
meta-analyses, and, in a second step, the most recent study. This 
FiGURE 1 | The hype cycle of preventive treatments for psychosis.
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was done to respect the hierarchy of the evidence. Research 
is conducted at different levels: primary research consists of 
original studies while secondary research comprises qualitative 
reviews, systematic reviews, and meta-analyses. Within meta-
analyses, network meta-analyses offer additional benefits over 
standard pairwise analyses in that the comparative efficacy of 
specific interventions can be estimated and ranked, even when 
two treatments have never been compared directly head-to-head 
(25). Furthermore, since network meta-analyses can improve 
the precision of estimates by allowing integration of both direct 
and indirect treatment effect estimates (26), it is recommended 
over pairwise meta-analyses by the World Health Organization 
as a basis for clinical guidelines (27). Therefore, network meta-
analyses should be considered the highest level of evidence in 
CHR-P treatment guidelines (28). Finally, Individual Participant 
Data meta-analyses should be considered as a higher level 
of evidence compared to aggregate-data meta-analyses (34), 
because they can improve the quality of the data, the analyses and 
thus the reliability of the results. Therefore, they are considered 
the gold standard. The quality of the meta-analyses identified 
through the literature search was assessed with the Assessing 
the Methodological Quality of Systematic Reviews (AMSTAR) 
tool (35). AMSTAR is a reliable and valid measurement tool 
to assess the methodological quality of systematic reviews. 
AMSTAR assess whether the systematic review was based on an 
“a priori” protocol, if authors run screening and data extraction 
in duplicates, if they run a comprehensive search, including 
grey literature, if they provided a complete list of both included 
and excluded studies (at full-text assessment), if they assessed 
quality of included studies, and accounted for such quality in 
conclusions, if used appropriate methods to pool and analyse 
data, if assessed publication bias, and if disclosed information on 
potential conflict of interest. AMSTAR score goes from 0 (low 
quality) to 11 (high quality) (35).
In a subsequent step, we additionally extracted the individual 
studies that were analysed by the corresponding meta-analysis 
that was included in the current umbrella review. Specifically, we 
included only randomised controlled trials with no restriction on 
study design, being published in the English language and with 
a sample size of at least 10 participants (36). Finally, to further 
provide a comprehensive view of current research in this field we 
systematically searched the clinicaltrials.gov using the keyword 
“psychosis risk” and filtering for randomised trials that were 
recruiting or active but not recruiting. The records were then 
summarized in a descriptive table.
Simulation of a Living Meta-analysis
Unfortunately, meta-analyses—even if based on individual 
participant data—are outdated as soon as new studies on the 
same topic emerge. Once published, only a minority of meta-
analyses are then updated within two years of publication (37). 
Such an inability to maintain recency may lead to significant 
inaccuracy in clinical practice which is not updated with 
evidence-based medicine. For example, by 2 years post-
publication, 23% of non-updated meta-analyses will have 
failed to incorporate new evidence that would substantively 
change its conclusions (38).
Cumulative meta-analysis, defined as updating a meta-
analysis whenever a new eligible RCT becomes available, can 
be used to address this (39). However, the problem is that the 
median time taken for a primary study to be incorporated into 
a meta-analysis ranges from 2.5 to 6.5 years (40). Thus, in 2014, 
“living systematic reviews” were proposed as a framework for 
continuously updating meta-analyses (41) (Figure 2).
Living meta-analyses are particularly indicated when the 
question to be addressed is essential to decision-making, 
when there is some uncertainty of the evidence, when new 
information is likely to change the findings, and when there is 
likely to be new evidence (42). All of these conditions apply to 
the CHR-P field. Crucially, living meta-analyses require bespoke 
analytical approaches that have been developed for sequential 
(interim) analyses of randomized clinical trials (43–46). We 
simulate here a living meta-analysis using the available RCTs. 
We employed methods which allow reducing the chances of 
inflating type-I errors (by using the alpha-spending monitoring 
boundaries (47)) and type II errors (by estimating the required 
“a priori anticipated information size” APIS), i.e., the minimum 
required sample size to detect an assumed minimal clinically 
important effect-size—as recommended by experts (48) —with 
a prespecified statistical power) (49). Furthermore, we used 
approximate Bayesian approaches to reduce the misestimation 
of heterogeneity (50). The results are presented in specific plots 
to facilitate the interpretation of the core findings.
RESULTS
Database for the Systematic Review
The initial literature search (Figure 3) retrieved 2,328 records, 
of which only 327 were meta-analyses and were screened on the 
basis of title and abstract reading.
Most of them were not focusing on CHR-P individuals or 
interventions, and only 14 full-text aggregate meta-analyses 
were eventually assessed for eligibility. There were no individual 
participant data meta-analyses.
One of these 14 meta-analyses was not reporting quantitative 
data (51) and 6 were overlapping with more recent meta-analyses 
(25, 52–56): these studies were thus excluded. Since two network 
meta-analyses addressed the same outcome and were published 
in the same year (2018) (57, 58), it was not possible to apply 
our exclusion criteria. Both network meta-analyses were thus 
included. The final database comprised seven meta-analyses: four 
aggregate-data network meta-analyses and three aggregate-data 
pairwise meta-analyses. Additionally, two errata were retrieved, 
but they were not counted as independent articles (59, 60). The 
full list of meta-analyses is listed in Table 1.
Effect of Preventive Treatments on clinical 
Outcomes in cHR individuals
Prevention of Psychosis Onset
An aggregate-data network meta-analysis published in 2018 
showed a lack of evidence to favor specific preventive treatments 
compared to each—and every—other for the prevention of 
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psychosis onset from a CHR state (67). These comparisons 
also included needs-based interventions or placebo. Some 
authors speculated that these findings would have changed 
if the Neurapro trial (28), which was classified as Omega-3 
+ needs-based intervention vs needs-based intervention [in 
line with other independent network meta-analyses (58, 62)] 
was classified as Omega-3 + Cognitive Behavioral Therapy 
(Cognitive Behavioral Case Management) + needs-based 
interventions vs cognitive behavioral therapy + needs based 
interventions (32). As already mentioned in the main paper 
(30), sensitivity analyses testing different definitions of the 
nodes did not change the results. For comprehensiveness, we 
further append in Figure S1 the forest plot of the network 
meta-analysis when the Neurapro trial was coded as Omega 
3 + Cognitive Behavioral Therapy (Cognitive Behavioral 
Case Management) + needs-based interventions vs cognitive 
behavioral therapy + needs-based interventions. The results 
remained unchanged.
Acceptability of Treatments
An aggregate-data network meta-analysis published in 2018 
showed a lack of evidence to favor any specific preventive 
treatment compared to every other (including also needs-based 
interventions or placebo) with respect to acceptability (defined as 
treatment drop-outs for any reason) (67).
Symptoms
Two independent aggregate-data network meta-analyses 
published in 2018 found lack of evidence to favor specific 
preventive treatments compared to each (and every) other for 
improving attenuated positive psychotic symptoms (58, 61).
Another aggregate-data network meta-analysis published 
in 2018 demonstrated no evidence to favor specific preventive 
treatments compared to each (and every) other for the 
FiGURE 3 | Study identification and selection (PRISMA flowchart).
FiGURE 2 | Living meta-analyses. Current (inner circle) and emerging (outer circle) evidence-based health knowledge ecosystems. The current health knowledge 
ecosystem is characterized by inefficiencies that hamper the flow of knowledge from health practice through primary research, evidence synthesis and guidelines, 
and finally back to impacts on health practice. The emerging health knowledge ecosystem is characterized by a continuous flow of knowledge between living 
components, including the growing importance of learning health care systems (a dynamic system which is continuously learning from new data), which together 
with traditional primary research will populate common data repositories. Living evidence services derived from these repositories, supporting living guidance and 
decision support systems will close a ‘‘living’’ health knowledge loop. Adapted from (41).
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improvement of attenuated negative psychotic symptoms (62). 
Some authors speculated that this meta-analysis showed “trend-
level” benefits for N-methyl-D-aspartate receptor (NMDAR) 
modulators compared to placebo (32). However, the 95%CI of 
the Standardized Mean Difference included the null hypothesis 
(from −1.09 to 0.02) (62). The authors of the network meta-
analysis in a following erratum clarified that neither efficacy 
nor effectiveness was statistically confirmed for any of the 
examined treatments and that “the abstract and text contained a 
misstatement regarding effectiveness” (60).
An aggregate-data pairwise meta-analysis published in 
2013 indicated that preventive treatments have no impact on 
depression in CHR-P individuals (26).
A further aggregate-data pairwise meta-analysis published 
in 2014 found that preventive treatments have no impact on 
symptom-related distress in CHR-P individuals (63).
Functioning
An aggregate-data pairwise meta-analysis published in 2018 
found no effect of available preventive treatments for the 
improvement of social functioning in CHR-P individuals (64). 
An aggregate-data pairwise meta-analysis published in 2014 
found no effect of preventive treatments on a broader level of 
functioning (63).
Quality of Life
The most recent meta-analysis to explore the impact of 
preventive treatments on quality of life in CHR-P individuals 
was published in 2014. There were no significant treatment 
effects reported (63).
Pooled vs Specific-Treatment Effect Sizes
None of the included meta-analyses estimated overall effect 
size across different categories of treatments (i.e. medications, 
psychological, dietary) pooled together.
Primary Outcomes investigated by 
Randomized controlled Trials in cHR-P 
individuals
As indicated in the methods, we further extracted details of the 
randomized controlled trials that were analyzed by the meta-
analyses included in the current umbrella review. A total of 20 
trials were retrieved (Table 2). The treatments tested were:
• needs-based interventions;
• omega-3 + needs-based interventions;
• ziprasidone + needs-based interventions;
• olanzapine + needs-based interventions;
• aripiprazole + needs-based interventions;
• amisulpride + needs-based interventions;
• Integrated Psychological Interventions;
• family therapy + needs-based interventions;
• D-serine + needs-based interventions;
• cognitive behavioral therapy, French & Morrison protocol + 
needs-based interventions;
• cognitive behavioral therapy, French & Morrison protocol + 
risperidone + needs-based interventions;
• cognitive behavioral therapy, van der Gaag protocol + 
cognitive behavioral therapy, French & Morrison protocol + 
needs-based interventions;
TaBLE 1 | Efficacy of treatments for CHR-P individuals. Overview of the most recent meta-analyses per clinical outcome (up to January 11th, 2019).
Outcome author year Type of evidence N of studies 
(max n of cHR 
individuals)a
aMSTaR 
rating
Finding
Transition to psychosis Davies et al. (30) 2018 Aggregate Network 
Meta-Analysis (RCTs)
16 (2, 035) 10/11 Lack of evidence to favor specific 
treatments
Acceptability Davies et al. (30) 2018 Aggregate Network 
Meta-Analysis (RCTs)
14 (1, 848) 10/11 Lack of evidence to favor specific 
treatments
Severity of attenuated positive 
psychotic symptoms
Davies et al. (61) 2018 Aggregate Network 
Meta-Analysis (RCTs)
14 (1, 707) 10/11 Lack of evidence to favor specific 
treatments
Devoe et al. (58) 2018 Aggregate Network 
Meta-Analysis (RCTs)
12 (1, 457)b 10/11 Lack of evidence to favor specific 
treatments
Severity of attenuated negative 
psychotic symptoms
Devoe et al. (60, 62) 2018 Aggregate Network 
Meta-Analysis (RCTs)
14 (1, 467)c 10/11 Lack of evidence to favor specific 
treatments
Depression Stafford et al. (26, 59) 2013 Aggregate Pairwise 
Meta-Analysis (RCTs)
5 (714) 9/11 No significant treatment effects at 
any time point
Symptom-related distress Hutton et al. (63) 2014 Aggregate Pairwise 
Meta-Analysis (RCTs)
Unclear 9/11 No significant treatment effects
Social functioning Devoe et al. (64) 2018 Aggregate Pairwise 
Meta-Analysis (RCTs)
9 (1, 040) 10/11 No treatment significantly improved 
social functioning
Functioning Schmidt et al. (25) 2015 Aggregate Pairwise 
Meta-Analysis (RCTs)
9 (869) 8/11 No significant treatment effects
Quality of life Hutton et al. (63) 2014 Aggregate Pairwise 
Meta-Analysis (RCTs)
Unclear 9/11 No significant treatment effects
asample sizes are based on the total sample sizes reported in the meta-analysis minus the sample size of any studies that were not included in their actual meta-analytic 
computations.
bsample size of Ising et al. (65) and the non-randomized arm of McGorry et al. (66) (N = 78) not included.
csample size computed by summing study sample sizes from Table 1 in Devoe et al. The non-randomized arm of McGorry et al. (66) (N = 78) was not included.
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• cognitive remediation therapy;
• computer games.
The primary outcome investigated by these trials as well as 
the rationale provided to support it are reported in Table 2. 
The vast majority (14/20, 70%) of randomized controlled trials 
defined the prevention of psychosis onset from a CHR-P state 
as their primary outcome. Three studies defined as primary 
outcome the reduction of attenuated psychotic symptoms (72, 
74, 76), two studies the improvement of cognitive functioning 
(73, 75), and one study the improvement of social functioning 
(71). The AMSTAR scoring for each meta-analysis included is 
reported in Table 2.
Ongoing clinical Trials identified in cHR-P 
individuals
Ongoing experimental randomized trials listed in clinicaltrials.
gov database that are currently recruiting CHR-P patient are 
summarized in Table 3. Other experimental treatments that are 
not yet listed in the clinicaltrials.gov database are presented below.
Oxytocin
Impairments of social cognition, which include emotional 
processing, theory of mind, and attributional style (82), are a 
primary cause of disability in psychosis (83) and respond poorly 
to current treatments. Emotional dysregulation and social 
cognition problems are also common in CHR-P individuals (84), 
are a key source of distress, and contribute to loss of functioning 
(85). Oxytocin, a neuropeptide, has numerous prosocial 
and antipsychotic-like effects in animals (86, 87). In healthy 
individuals, oxytocin promotes interpersonal trust (88), social 
interactions, and emotional bonding while decreasing arousal 
and aversion towards negative or threatening social stimuli (89) 
[for review see (90)]. In patients with psychosis, oxytocin has been 
shown to improve emotional recognition and social dysfunction 
and may ameliorate psychotic symptoms (91), although the 
TaBLE 2 | Primary outcome with rationale as declared in the randomized controlled trials of treatments for CHR-P individuals.
author Primary outcome Rationale supporting the primary outcome
Addington et al. (68) Prevention psychosis Psychological interventions might be expected to be promising in the pre-psychotic period when 
the symptoms are less severe and also less specific
Amminger et al. (23) Prevention psychosis Intervention in at-risk individuals holds the promise of even better outcomes, with the potential to 
prevent full blown psychotic disorders.
Bechdolf et al. (22) Prevention psychosis Prevention efforts in individuals at imminent risk of schizophrenia can reduce or prevent the 
devastating effects of the disorder
Bechdolf et al. (69) Prevention psychosis Effective interventions for CHR-P individuals are needed in order to reduce or prevent the 
devastating effects of the disorder
Cadenhead et al. (70) Prevention psychosis Replication study testing the efficacy of dietary interventions as defined by Amminger et al. (23)
Choi et al. (71) Social functioning Providing cognitive remediation during a putative prodromal stage may improve social functioning 
and have some value in reducing the risk of psychosis onset
Kantrowitz et al. (72) Reduction of attenuated 
negative psychotic symptoms
Negative symptoms and cognitive deficits frequently persist and contribute substantially to impaired 
functional outcome.
Loewy et al. (73) Cognitive functioning The variability in outcomes for CHR-P patients requires treatments that offer the prospect of high 
benefit and low risk
McGlashan et al. (20) Prevention psychosis The chronicity of schizophrenia determines the primary rationale for studies of early intervention for 
this disorder
McGorry et al. (19) Prevention psychosis Progression to psychosis is neither inevitable nor predetermined and it may be possible to delay the 
onset of psychosis
McGorry et al. (28, 29) Prevention psychosis Treatment strategies should relieve distress, improve functioning, and reduce the risk for 
progression to a psychotic illness
Miklowitz et al. (74) Reduction of attenuated 
positive psychotic symptoms
Intervention during the high-risk period may reduce subthreshold psychotic symptoms, enhance 
social and role functioning, and, over the long term, prevent or delay conversion to episodes of 
psychosis
Morrison et al. (21) Prevention psychosis Specific pharmacotherapy and psychotherapy may be associated with a reduction in progression 
to psychosis in CHR-P people
Morrison et al. (27) Prevention psychosis Effective interventions to prevent or delay this transition are needed because of the significant 
personal, social, and financial costs associated with the development of psychosis
Piskulic et al. (75) Cognitive functioning Given that deficits in cognition are related to poor functional outcome in CHR-P, cognition is a good 
treatment target
Ruhrmann et al. (76) Reduction of attenuated 
positive psychotic symptoms
Attenuated psychotic symptoms are the most important indicators of imminent risk; their 
disappearance may be associated with lower rates of transition to psychosis
Stain et al. (77) Prevention psychosis The CHR-P criteria provide an important opportunity for early intervention in preventing or delaying 
the onset of psychosis and reducing the social and economic burden associated with long-term 
mental health problems
van der Gaag et al. (65, 78) Prevention psychosis Postponement or prevention of the transition to frank psychosis is the main goal: early detection is 
of little use without an effective intervention.
Woods et al. (79, 80) Prevention psychosis To investigate the safety and efficacy of ziprasidone in delaying or preventing conversion to 
psychosis among individuals meeting CHR-P criteria
Yung et al. (81); McGorry 
et al. (66)
Prevention psychosis Cognitive therapy and/or low-dose antipsychotic administered during the prodromal phase of 
schizophrenia may prevent or delay the onset of full-blown illness.
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TaBLE 3 | Ongoing trials in CHR-P individuals.
Trial title; clinicalTrials.gov 
identifier
Population (age); 
instrument
Trial arms allocation and 
masking
Duration Sample 
size
Primary outcome
The Role of Antidepressants 
or Antipsychotics in Preventing 
Psychosis: Fluoxetine vs 
Aripiprazole Comparative Trial 
(FACT). NCT02357849
CHR-P (12-25); 
SIPS
1. Fluoxetine; 2. aripiprazole Randomized 
(participant, care 
provider, investigator 
outcomes assessor)
24 weeks 48 Time to either 
all-cause-
discontinuation 
or need to 
add another 
psychotropic agent
Multimodal Prevention of 
Psychosis - Investigating 
Efficacy of N-Acetylcysteine and 
Psychotherapy in CHR-Patients 
(ESPRIT-B1). NCT03149107
CHR-P (18-40); 
SIPS or SPI-A
1. Integrated Preventive 
Psychological Intervention 
plus N-Acetylcysteine; 
2. Psychological 
stress management 
and N-Acetylcysteine; 
3. Integrated Preventive 
Psychological 
Intervention and placebo; 
4. Psychological stress 
management and placebo
Randomized 
(participant, investigator, 
outcomes assessor)
6 months 200 Transition to 
psychosis
Randomized Controlled Trial 
of Aspirin vs Placebo in the 
Treatment of Patients With 
the Clinical Risk Syndrome for 
Psychosis. NCT02047539
CHR-P (19-35); 
SIPS
1. Aspirin (2-Acetoxybenzoic 
acid); 2. placebo
Randomized 
(participant, care 
provider, investigator 
outcomes assessor)
12 weeks(a) 40 Symptoms 
improvement
Placebo-controlled Trial in 
Subjects at Ultra-high Risk for 
Psychosis With Omega-3 Fatty 
Acids in Europe (PURPOSE). 
NCT02597439
CHR-P (13-20); 
CAARMS
1. Omega-3 fatty acids; 
2. placebo
Randomized 
(participant, care 
provider, investigator)
6 months 220 Transition to 
psychosis
Effects of Neurocognitive and 
Social Cognitive Remediation 
in Patients at Ultra-High 
Risk of Psychosis (FOCUS). 
NCT02098408
CHR-P (18-40); 
CAARMS
1. Standard treatment 
+ cognitive remediation; 
2. standard treatment
Randomized 
(investigator, outcomes 
assessor)
6 months 126 Cognitive 
functioning
Cognitive Behavioral Social Skills 
Training for Youth at Risk of 
Psychosis. NCT02234258
CHR-P (14-30); 
SIPS
1. Cognitive 
behavioral social skills; 
2. psychoeducation
Randomized (outcomes 
assessor)
18 weeks 225 Social functioning
Decreasing Risk of Psychosis 
by Sulforaphane (DROPS Trial). 
NCT03932136
CHR-P (15-45); 
SIPS
1. Sulforaphane; 2. placebo Randomized 
(participant, care 
provider, investigator, 
outcomes Assessor)
52 weeks 300 Transition to 
psychosis
Targeted Cognitive Training in 
Clinical High Risk (CHR) for 
Psychosis. NCT02404194
CHR-P (15-30); 
SIPS
1. Targeted cognitive 
training; 2. computer game
Radomized (participant, 
investigator, outcomes 
assessor)
10 weeks 76 Cognitive 
functioning
Minocycline and/or Omega-3 
Fatty Acids Added to Treatment 
as Usual for At Risk Mental 
States (NAYAB). NCT02569307
CHR-P (16-35); 
CAARMS
1. Minocycline; 2. omega-3 
fatty acids; 3. treatment as 
usual
Randomized 
(participant, care 
provider, investigator)
6 months 320 Transition to 
psychosis
The Staged Treatment in Early 
Psychosis Study (STEP). 
NCT02751632
CHR-P (15-25); 
CAARMS
staged treatment: 
1. support and problem 
solving therapy; 
2. cognitive behavioural 
case management; 
3. cognitive behavioural 
case management plus 
fluoxetine; 4. cognitive 
behavioural case 
management plus placebo
Randomized 
(participant, investigator, 
outcomes assessor)
up to 12 
months
340 Global functioning
Exercise and Markers of Medial 
Temporal Health in Youth at 
Ultra High-risk for Psychosis. 
NCT02155699
CHR-P (16-24); 
SIPS
1. Exercise 1; 2. exercise 2; 
3. waiting list
Randomized (outcomes 
assessor)
3 months 45 Brain volume
(Continued)
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hope of its potential as a treatment in established psychosis has 
been somewhat stifled by recent negative meta-analytic findings 
(92, 93). Nevertheless, neuroimaging studies demonstrate that 
oxytocin can modulate various indices of brain function, both 
task-specific and at rest, and in regions critically implicated in the 
onset of psychosis, such as limbic and midbrain brain regions (94–
96). A randomized, double-blind, placebo-controlled, crossover 
acute-challenge MRI study has recently shown that oxytocin 
modulates hippocampal perfusion in CHR-P individuals (97), 
providing the first neurophysiological evidence for disease-target 
engagement. Further studies are ongoing that will better clarify 
the neurobiological effects of oxytocin in this patient population.
Cannabidiol
Cannabidiol is a major constituent of cannabis. In contrast to 
the psychoactive cannabinoid Δ9-tetrahydrocannabinol (THC), 
the non-psychoactive compound cannabidiol shows anxiolytic 
and potential antipsychotic properties. Early findings that 
administration of cannabidiol reduced psychotic symptoms in 
patients with established psychosis led to the suggestion that it may 
also have therapeutic potential in those at CHR-P (98, 99). Interest in 
cannabidiol is enhanced by its unique mechanism of action compared 
to established antipsychotics, as well as its distinct lack of serious 
adverse effects. A randomized controlled trial using cannabidiol 
and MRI in CHR-P individuals has recently been completed. In 
33 CHR-P individuals and 19 healthy controls, cannabidiol was 
found to modulate activation of brain regions strongly implicated 
in the onset of psychosis during verbal learning, such as the 
striatum, medial temporal cortex, and midbrain (100). These 
early results support the view that cannabidiol may be an effective 
treatment strategy. Future large-scale randomized controlled 
trials involving cannabidiol are expected from different research 
centers worldwide.
Simulation of the Living Meta-analysis
The results of the simulated living meta-analyses is provided in 
Figures 4 and 5.
Figure 4 illustrates the theoretical results of a cumulative 
living meta-analysis investigating the efficacy of CBT versus 
needs-based intervention on the risk of developing psychosis 
at 6-months, for a treatment which can halve the risk of 
psychosis (Risk Ratio Reduction, RRR = 0.5). The a priori 
information size (APIS) plotted in Figure 4 represents the 
sample size needed to investigate this effect, with an alpha 
of 0.05 and power of 0.9 (given the high uncertainty of the 
field the safest approach would be to plan a high power). 
The randomized controlled trials are analyzed in order 
of publication time, with the effect size of the (theoretical) 
living meta-analysis being updated every time a new trial 
is published. As shown in Figure 4, all updates of the living 
meta-analysis are reporting non-significant results that never 
cross the monitoring boundaries (lack of evidence), and that 
the APIS needed (given the minimal clinically relevant RRR, 
alpha and power) was not reached. Had a living meta-analysis 
been planned and performed, it would have shown that all 
published CBT trials were underpowered for testing the 
prevention of psychosis at 6-month follow-up under the above 
parameters (i.e. were false negatives). Figure 4 investigates 
the preventive effect of CBT versus needs-based interventions 
TaBLE 3 | Continued
Trial title; clinicalTrials.gov 
identifier
Population (age); 
instrument
Trial arms allocation and 
masking
Duration Sample 
size
Primary outcome
Glutamate Reducing 
Interventions in Schizophrenia. 
NCT03321617
CHR-P (18-30); 
NA
1. pomaglumetad methionil 
40 mg, 2. pomaglumetad 
methionil 80 mg, 3. 
pomaglumetad methionil 
120 mg, 4. pomaglumetad 
methionil 160 mg
Randomized 
(participant, investigator, 
outcomes assessor)
2 weeks 50 Cerebral blood 
volume
Transcranial Direct Current 
Stimulation Coupled With Virtual 
Rehabilitation for Negative 
Symptoms in At-Risk Youth. 
NCT02951208
CHR-P (16-30); 
SIPS
1. Active Transcranial Direct 
Current Stimulation Coupled 
With Virtual Rehabilitation; 
2. sham conditions
Randomized 
(participant, care 
provider, investigator 
outcomes assessor)
4 weeks 22 Symptoms 
improvement
Neurofeedback Processing 
Speed Training to Improve Social 
Functioning in Teenagers and 
Young Adults at Clinical High Risk 
for Psychosis. NCT03447548
CHR-P (12-25); 
SIPS
1. Neurofeedback 
processing speed training, 
2. control
Radomized (participant, 
outcomes assessor)
NA 105 Cognitive 
functioning
A Phase II Randomised, 
Double-blind, Placebo-controlled 
Study to Evaluate the Efficacy, 
Safety, and Tolerability of Orally 
Administered BI 409306 During a 
52-week Treatment Period as an 
Early Intervention in Patients With 
Attenuated Psychosis Syndrome. 
NCT03230097
DSM-5-APS (16-
30); DSM-5
1. BI 409306; 2. placebo Randomized 
(participant, investigator)
52 weeks 300 Time to remission
(a)not clear.
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in CHR-P individuals at 12 months. With the second trial 
there are significant results but a spurious effect because the 
curve does not cross the monitoring boundary (false positive 
result). The fourth and fifth trials produce significant results 
that cross the monitoring boundaries before the information 
sample is reached (true positive results). However, with the 
addition of the sixth and seventh trials the required APIS is 
almost met, the monitoring threshold is not crossed, and the 
result becomes non-significant (this could be a true negative 
result). Importantly, as noted above, these estimates relate to 
relatively large effect sizes (RR = 0.5). Current interventional 
CHR-P literature to date has not been powered to detect 
smaller effect sizes.
DiScUSSiON
This is the first umbrella review of the evidence for preventive 
interventions in CHR-P individuals. Seven meta-analyses that 
were investigating preventive treatments in CHR-P individuals 
were included. None of them produced pooled effect sizes 
across psychological, pharmacological, or other types of 
interventions. The outcomes analyzed encompassed: risk of 
psychosis onset from a CHR-P state, acceptability of treatments, 
severity of attenuated positive and negative psychotic symptoms, 
depression, symptom-related distress, social functioning, general 
functioning, and quality of life. There was no evidence to favor 
any of the current preventive interventions over each—and any—
other to improve any of these clinical outcomes. These meta-
analyses were based on 20 randomized controlled trials. The vast 
majority of them (70%) defined the prevention of psychosis onset 
as their primary outcome (first-order issue) of interest. Several 
new trials are ongoing in this population, reflecting the high 
interest in this field. Simulation of a living meta-analysis did not 
change the interpretation of the current evidence.
The following sections interpret these findings in the context 
of the overall evidence for interventions in CHR-P individuals, 
the use of pooled vs treatment-specific effect sizes, the 
definition of primary and secondary outcomes in the published 
trials, and future recommendations to advance clinical research 
in this field.
Evidence-Based Efficacy of Preventive 
Treatments for cHR-P individuals
As noted in the introduction, it has been argued that the 
CHR-P paradigm has the capacity to i) identify people at 
incipient risk for psychosis, ii) improve their levels of distress 
and functioning, and iii) reduce their risk of progression to 
sustained psychotic disorder (32). It is true that the CHR-P 
paradigm has allowed the first prospective identification 
FiGURE 4 | Example of sequential meta-analysis testing the preventive efficacy 
of CBT in CHR-P individuals. Plotted are the Randomized Controlled Trials of 
CBT vs Needs Based Intervention (NBI) in CHR-P patients that reported risk 
of psychosis onset at 6-month (part a) and 12 months (part B). The blue line 
represents the Z-value of each interim meta-analysis, the green line indicates 
the statistical significance threshold and the dotted red line the monitoring 
boundary. The red vertical line represents the a priori information size (APIS), 
i.e., the required sample size to detect a Relative Risk Reduction (RRR) = 0.5 
with statistical power 0.9 on the risk of psychosis. Estimated using the package 
metacumbounds (101) and the previously published meta-analytical results (30).
FiGURE 5 | Clinical Stratification of Pretest Risk Enrichment in Individuals 
undergoing a Clinical High Risk assessment (102).
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of individuals at risk of developing psychosis in clinical 
psychiatry. The achievements of the CHR-P paradigm have 
been extensively celebrated over the past years (3). At the same 
time, some important challenges have emerged. As illustrated 
by the trough of disillusionment phase in the Hype Cycle in 
Figure 1, the actual ability of specialized CHR-P clinics (4) to 
detect individuals at risk for psychosis is limited. An original 
study has estimated that only around 5% of individuals who 
will later develop a first episode of psychosis in secondary 
mental health care were detected by the local services at the 
time of their CHR-P stage (15, 103). Front-line youth mental 
health services, as opposed to specialized CHR-P clinics such as 
the OASIS, can be expected to detect more at-risk individuals. 
However, the limited evidence indicates that even youth 
mental health services can detect only 12% of first episode 
cases at the time of their CHR-P stage (104). It is therefore 
clear that we need to improve our ability to detect CHR-P 
individuals in secondary mental health care, primary care, and 
in the community. Some experimental approaches have been 
validated, which include automatic risk calculators for use in 
mental health trusts (57, 103, 105) or in the community (106).
Conversely, there is no evidence that current treatments are 
effective in improving the level of distress and functioning of 
CHR-P individuals. The most updated meta-analytical evidence 
summarized in Table 2 shows no evidence to favor any preventive 
treatments over each (and any) other for improving any of the 
clinical outcomes that are relevant for CHR-P individuals: risk of 
developing a first episode of psychosis, acceptability of treatments, 
severity of attenuated positive or negative psychotic symptoms, 
depression, symptom-related distress, level of social functioning, 
level of general functioning, and quality of life. Although CHR-P 
patients may improve in their symptoms pre-post treatment, 
there are no substantial differences across interventions (which 
also includes control conditions). Importantly, although the 
meta-analyses presented in Table 2 were conducted by different 
and independent research teams, their results converge. For 
example, two independent meta-analyses both concluded that 
there is no evidence to favor specific treatments over each 
other for improving attenuated positive psychotic symptoms in 
CHR-P individuals (58, 61). Unfortunately, there is no robust 
evidence that current treatments can improve functional 
levels in these patients. The most recent meta-analysis to have 
explored this outcome concluded that Cognitive Behavioral 
Therapy did not significantly improve social functioning at 6, 
12, or 18 months; Omega-3 did not significantly improve social 
functioning at 6 or 12 months and Cognitive Remediation did 
not significantly improve social functioning at 2- to 3-month 
follow up (64). Lack of evidence for a symptomatic effect of 
preventive treatments in CHR-P individuals is also in line with 
our limited understanding of their mechanism of action at a 
neurobiological or psychological level (107). An independent 
pairwise meta-analysis published by the Cochrane group after 
completion of the current study has confirmed these findings. 
The study concluded that “there was no convincing, unbiased, 
high-quality evidence to suggest that any type of intervention is 
of value” for CHR-P people (108).
apples, Oranges, and the Production of 
clinically Meaningless Pooled Effect-Sizes
A second issue, as detailed in the introduction (32), is the 
possibility that if the two recent network meta-analyses (30, 61) 
had pooled together psychosocial and pharmacological trials, 
statistically significant findings could have emerged (32). On 
a statistical and conceptual level, if the randomized controlled 
trials are all pooled together, there could be no “network” meta-
analysis comparing specific nodes against each other but just a 
simple meta-analysis of the average efficacy of all treatments. On 
a pragmatic level, it is indeed true that these two meta-analyses 
(30, 61) did not even estimate a pooled effect size for all types of 
treatments, because this has little clinical interest and, as such, 
it was deliberately not planned in the a priori protocol of these 
studies (109). These meta-analyses were conducted to estimate 
the level of evidence with respect to specific clinical questions. 
Since preventive treatments for CHR-P individuals are highly 
heterogeneous, pooled effect sizes are clinically meaningless 
and cannot be used to inform treatment guidelines. Although 
a statistically significant pooled effect size may mean that 
interventions overall work, how would a clinician, who needs 
to decide on the best treatment to offer to a CHR-P patient, 
fare when interpreting a pooled effect size which has been 
estimated across pharmacological, psychological, and dietary 
interventions vs heterogeneous control conditions? Such an 
effect size would, at best, suggest that “any type of experimental 
treatment” is better/worse/similar than “any type of control 
condition”. This is some information (i.e. the intervention seems 
on average to work), but it is clearly useless from a clinical 
standpoint. Treatment guidelines need to be as specific as 
possible because clinicians, healthcare providers, and patients 
rely on them for clear direction and education on the best ways 
of adhering to them. Three previous aggregate pairwise meta-
analyses were cited by the authors as support for pooling effect 
sizes across pharmacological and psychological categories of 
treatments (32). The first meta-analysis cited did not estimate 
any pooled effect sizes at all (26). Rather, this meta-analysis 
performed separate pairwise comparisons of specific preventive 
interventions, such as cognitive behavioral therapy vs supportive 
counselling (26). The second meta-analysis did compute 
significant pooled effect sizes and concluded that “receiving any 
of the focused treatment (53)” was associated with a reduced 
risk of psychosis onset. This clearly demonstrates the criticalities 
above: What exactly is a “focused treatment” and how should it 
be implemented in clinical routine? Because the authors could 
not answer such a question, they stated that their results did 
“not allow recommendation for any specific treatment” (53). 
This further demonstrates that pooled effect sizes in the CHR-P 
field are clinically meaningless and cannot inform treatment 
recommendations. It is, therefore, important to examine the 
efficacy of specific treatment effects in CHR-P individuals. 
Accordingly, the rationale for conducting the first randomized 
controlled trial in the CHR-P population was based on the need 
to examine more “specific interventions”—page 922 in Ref. (19). 
The third meta-analysis which was cited did compute a pooled 
effect size across cognitive behavioral therapy plus risperidone, 
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olanzapine, omega-3, integrated psychotherapy (which included 
group skills training, cognitive remediation and multifamily 
psychoeducation in addition to cognitive behavioral therapy), 
and cognitive behavioral therapy compared to treatment as 
usual (52). In this case, the overall effect size was reported in 
Figure 2 on page 60 (52) and it was inaccurately termed, in the 
figure itself, as “cognitive behavioral therapy” vs “treatment as 
usual”, ignoring the effect of risperidone, olanzapine, and dietary 
interventions (52). Furthermore, when this meta-analysis 
stratified the effect size by type of interventions, it concluded 
that “the subset of CBT-based interventions is associated with 
a pooled RR of 0.52 (95% CI = 0–79)”, and reported 95% 
confidence intervals which included the null hypothesis (RR = 
1) (52). The lack of statistical significance could be due to the 
lower statistical power because of the stratification, yet this 
finding does not support a robust preventive effect of CBT-based 
interventions. This demonstrates that pooled effect sizes are not 
only of difficult clinical interpretability but also at very high risk 
of reporting biases.
Interventions for CHR-P are intrinsically highly 
heterogeneous because they include different therapeutic 
components. This is due to the fact that when interventions 
were originally introduced in the first randomized controlled 
trial, the strategy adopted was to “include the best-bet 
specific therapies in a single enhanced intervention package 
to determine whether it was possible to delay the onset of 
psychosis” (19). The subsequent randomized controlled trials 
have followed this approach by testing different packages, each 
of which was characterized by specific therapeutic components. 
This issue is evident, for example, in the case of different types 
of psychological therapies, which have been defined as “black 
boxes” (110). The additional and substantial problem with 
using pooled effect sizes in the CHR-P field is that the control 
group, traditionally termed as “treatment as usual” (52), is 
per se poorly standardized and largely dependent on local 
service configurations and the availability of specific resources 
or competences (67). For example, treatment as usual may 
encompass supportive psychotherapy primarily focusing on 
pertinent issues such as social relationships and vocational or 
family problems, case management, providing psychosocial 
assistance with accommodation, education or employment, 
brief family psychoeducation and support, medications 
other than antipsychotics, or clinical monitoring and crisis 
management (26). Network meta-analyses can be used to 
deconstruct the subcomponents of needs-based-interventions. 
Network meta-analyses offer additional benefits over standard 
pairwise analyses in that the comparative efficacy of specific 
interventions can be estimated and ranked, even when two 
treatments have never been compared directly head-to-head 
(111). Furthermore, network meta-analyses can improve the 
precision of estimates by allowing integration of both direct 
and indirect treatment effect estimates (112). The World 
Health Organization recommends network meta-analyses 
over pairwise meta-analyses as a basis for informing clinical 
guidelines (113). Therefore, network meta-analyses should be 
considered the highest level of evidence in CHR-P treatment 
guidelines (114). Because of these reasons, over recent years 
independent research teams have used network meta-analytical 
approaches to investigate the specific efficacy of preventive 
interventions for CHR-P individuals. Importantly, the current 
umbrella review demonstrates that none of them has produced 
pooled effect sizes (58, 60, 62, 64). This further provides 
independent validation that pooled effect sizes across different 
types of treatments should not be estimated when conducting 
treatment meta-analyses in the CHR-P field.
The Opportunistic (in)Significance of 
Preventing the Onset of Psychosis
The third issue raised by some authors was that recent meta-
analyses have focused on “second-order issues,” namely 
transition to psychosis in CHR-P individuals (32). The relegation 
of the prevention of psychosis to a second-order clinical outcome 
conflicts with the previous two decades of experimental research 
in this field. The extent to which randomized controlled trials 
in CHR-P individuals have prioritized prevention of psychosis, 
compared to other outcomes, is reported in Table 2. All twenty 
randomized controlled trials but four, corresponding to 70% of 
published trials, have focused on preventing the first onset of 
psychosis in CHR-P individuals as their primary outcome. Even 
the trials that did not primarily focus on preventing transition to 
psychosis still recommended investigation of whether the specific 
interventions could affect conversion rates (74) and modify the 
course of disease (72).
Until now, there has been a converging consensus in the 
CHR-P field that prevention of psychosis was the foremost 
outcome and the ultimate aim of the entire paradigm. Authors 
of randomized controlled trials in CHR-P individuals have 
declared that the goals of early detection are: 1) postponement 
or prevention of the transition to frank psychosis, 2) reduction 
of the duration of untreated psychosis to a minimum in patients 
who develop florid psychosis, and 3) prevention of delay to 
accessing mental health services (78). The authors also explicitly 
acknowledged that prevention of psychosis is the main goal (78). 
In line with this, outcomes other than the onset of psychosis have 
been poorly operationalized in the CHR-P field. For example, 
there is no clear definition for symptomatic remission or good 
outcomes in CHR-P patients. The importance of preventing 
the onset of psychosis in CHR-P individuals has been further 
endorsed worldwide and supported by consensus papers (3). 
Notably, the first randomized controlled trial in these patients 
aimed at determining whether it was possible to delay the onset 
of psychosis (19). The rationale given was overall pointing to 
the fact that this would be the most important way to alter 
the course of the disorder and eventually improve the lives of 
many patients. Such accumulating evidence clearly indicates 
that the prevention of psychosis has been “the” first-order issue 
in the CHR-P and not at all a second-order issue, as argued 
(32). It does not seem justified to downgrade the relevance of 
preventing psychosis in CHR-P individuals just because recent 
meta-analyses have not found robust evidence to favor specific 
preventive interventions (including also control conditions such 
as needs-based interventions). It has been argued that recent 
meta-analyses are “pessimistic” and have “distracted from the 
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key message” of the research literature, which is “in need of 
positive findings pointing to better outcomes” (32). Evidence 
synthesis is conducted to test the robustness of findings on a 
determinate topic, and not to meet the needs of scientists and 
researchers. Reporting negative as well as positive findings is 
equally important. By systematically identifying and addressing 
gaps in knowledge, “negative” evidence syntheses such as 
these may, in fact, help to advance the field. For example, in 
taking a closer look, recent meta-analyses have concluded 
that owing to large confidence intervals, the actual efficacy of 
treatments for preventing psychosis is mostly indeterminate 
(30). Some effective signal in treatments’ efficacy may have been 
missed because of the large clinical heterogeneity (67) of the 
population being investigated. In this sense, these results are not 
at all pessimistic, but they rather call for a new generation of 
experimental research in this field (see below). Conversely, the 
claim that prevention of psychosis is a second-order issue could 
discourage future trials from exploring this relevant outcome 
and the current uncertainty in the meta-analytical estimates may 
remain unresolved. On a more conceptual level, there is some 
consensus that psychosis onset as defined categorically is an 
arbitrary concept (115–117) and that it should be better refined 
or complemented by other relevant outcomes, such as severity of 
attenuated symptoms, disability, and functional outcomes. Yet, 
prevention of psychosis should remain the cornerstone and the 
most important outcome for the CHR-P field, complemented 
by other outcomes. Downgrading—or at worst, dropping—
such a primary outcome would be an indirect demonstration 
that current CHR-P research has approached the lowest depths 
of the through of disillusionment, with complete failure with 
respect to its ability to prevent psychosis. It would also prove 
that preventive psychiatry is different from other branches of 
medicine. For example, lack of effective treatments to prevent 
dementia (118) from a mild cognitive impairment stage has not 
triggered neurologists to claim that prevention of dementia itself 
should be downgraded to a second-order issue (instead it has 
become a priority for public health) (119).
Towards the Slope of Enlightenment 
and the Next Generation of Experimental 
Therapeutics
As noted above, some authors have used recent findings to claim 
that the CHR-P paradigm should be completely abandoned. 
Such a claim seems too intransigent and not evidence-based. 
For example, by using the same criteria we should claim that 
integrated clinical services for first episode of psychosis 
should be dismantled, given that there is no evidence that 
they can reduce the duration of untreated psychosis (120) or 
prevent relapse (1). The absence of evidence is not evidence 
of absence (121). Furthermore, dismissing two decades of 
CHR-P research is not in line with the progressive nature 
of  medical knowledge. As clarified in Figure 1, the trough 
of disillusionment often precedes the slope of enlightenment 
and the plateau of stable knowledge. The uncertain stage of 
knowledge which is typically associated with the trough of 
disillusionment is not specific to the CHR-P state; rather, it 
has also been observed in other branches of clinical medicine, 
such as cancer prevention (122). It is thus important to use our 
understanding of current limitations to advance knowledge, 
rather than hinder it.
The Essential Role of Risk Enrichment During 
Recruitment
The psychometric instruments traditionally used to ascertain 
the presence of a CHR-P state have been validated worldwide 
and, overall, have demonstrated excellent prognostic accuracy 
(AUC at 3 years: 0.9), comparable to that of other prognostic 
instruments employed in organic medicine (7). Yet, such an 
excellent prognostic accuracy is mostly due to the excellent 
sensitivity (96%) of CHR-P instruments to detect a state of risk 
for psychosis in help seeking patients who underwent some 
risk enrichment (i.e. pretest risk=15% at 3-year). Therefore, 
they are able to detect nearly all individuals who would develop 
psychosis, and consequently, nearly all individuals testing 
negative should be individuals who would not develop psychosis. 
In other words, a negative CHR-P assessment is associated 
with a very small probability of developing psychosis (1.56% at 
3-year, negative likelihood ratio of 0.09) (7, 123). Conversely, 
the CHR-P instruments have a poor specificity (47%) and thus 
half of the individuals who would not develop psychosis might 
be false positives. Therefore, among individuals testing positive, 
most would not develop psychosis, or in other words, a positive 
CHR-P is still associated with a relatively small probability of 
developing psychosis (26% at 3-year, positive likelihood ratio of 
1.82) (7, 123). Therefore, there is only a limited predictive gain 
in testing positive at a CHR-P assessment. As a consequence, 
CHR-P instruments should be used in samples that have 
already been enriched in their initial risk of psychosis and not 
as screening methods in the general population (see below) (7, 
124). Otherwise, the global number of false positives would be 
so high, that most individuals with positive testing would be 
false positives (124). When individuals undergoing a CHR-P 
assessment are recruited from mental health services, they 
accumulate several risk factors for the disorder (6) which 
increase their level of risk to 15% at 3 years, compared to the 
0.43% 3-year risk in the local age-matched general population 
(9, 102). This level of risk is also termed “pretest risk” because it 
is ascertained in the whole group of people undergoing a CHR-P 
assessment before the results of the assessment itself are known 
(123). The pretest risk in individuals recruited through mental 
health services (i.e. measured in naturalistic studies, excluding 
randomized controlled trials) is 15% at 3 years, worldwide (5). 
However, such an estimate is highly variable, with study estimates 
ranging from 3% to 49%, because it is based on unstandardized 
idiosyncratic recruitment strategies (5). When these individuals 
are assessed (tested), those meeting CHR-P criteria will have a 
26% risk of developing psychosis at 3 years (1.7-fold increase 
from the pretest of 15%) and those not meeting CHR-P criteria 
will have a 1.56% risk of developing psychosis at 3 years (10-fold 
decrease from the pretest risk of 15%). As indicated in Table 4, 
assuming an alpha of 0.05, power of 90% (a higher power of 90% 
is recommended given the high uncertainty of this field; see 
Table S1 for sample size estimations using 80% power), 2-sided 
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test, it is possible to estimate the sample size which is required 
to test a new experimental treatment to prevent psychosis 
against treatment as usual (e.g. needs-based intervention). If 
the experimental treatment is able to halve the risk of psychosis 
(risk ratio = 0.5), 2,368 CHR-P individuals [conservatively using 
the 3% lower bound of the study estimates to avoid additional 
underpowered negative trials (31)] are required to complete the 
trial. After considering some attrition due to lost to follow-up 
(e.g. 20%), the final sample size would be of 2,842 CHR-P 
individuals. The problem is that this sample size is based on the 
pretest estimate from naturalistic studies that more likely represent 
the whole population seeking help at specialized CHR-P clinics. 
When CHR-P individuals detected by these specialized clinics 
are recruited into randomized controlled trials, it is likely that 
additional sampling biases would apply, further reducing the risk 
enrichment. For example, the push towards recruiting sufficient 
numbers of trial participants within a fixed period of time may 
lead to more intensive outreach campaign in the local community, 
which are well known to dilute the pretest risk (125). In other 
words, using unstructured recruitment strategies it may not be 
sufficient to recruit 2,842 CHR-P in new trials to be sufficiently 
powered to test preventive effects of magnitude 0.5. Furthermore, 
such a study would not be powered to test smaller effect sizes. If the 
efficacy of the preventive is lower, for example, if the experimental 
treatment is able to reduce the risk of psychosis onset by only 40% 
(risk ratio = 0.6) or 30% (risk ratio = 0.7), 3,942 and 7,436 CHR-P 
patients are needed to complete the trial (ignoring attrition), 
respectively. If individuals undergoing a CHR-P assessment are 
mostly recruited from the community, they will have accumulated 
less or no risk factors for psychosis (67) and their pretest risk would 
be 0.43% at 3 years. Following the estimates reported in Table 4, 
the sample size required for a similar randomized controlled trial 
would exceed 17,908 CHR-P individuals (ignoring attrition). In 
fact, CHR-P instruments do not work well when they are applied 
outside clinical samples that have already undergone some pretest 
risk enrichment (124, 125). As noted above, the way individuals 
are recruited (for undergoing a CHR-P assessment) drives the level 
of risk enrichment (5) and ultimately, impacts the statistical power 
of the trial. For example, the Neurapro trial has observed a risk of 
psychosis onset of about 14% at 3.4 years (29) in CHR-P individuals 
who had received the control condition, which suggests a pretest 
risk of 8.2% (we estimated the pretest risk of the sample as the 
transition risk of the control condition, assuming that there was 
no effect of needs based intervention). Under those circumstances, 
796 CHR-P individuals would be needed to detect a 50% decrease 
in risk in the experimental condition, which exceeded the sample 
size employed by the trial. If there is some effect of the needs based 
intervention in the control condition, [as speculated by the authors 
(28)], then the pretest risk would be lower than that we estimated, 
and therefore the required sample size would be larger.
It is therefore possible that the low level of risk for psychosis 
decreased the statistical power of the trial to detect small signal 
effects associated with the experimental treatments. Lack 
of statistical power because of a poor level of psychosis risk 
may actually be one of the causes of the negative randomized 
controlled trials in this population (31) and of the associated 
large 95% confidence intervals that have been observed in 
the last network meta-analysis (30). The main problem is that 
recruitment strategies in this field are idiosyncratic and poorly 
standardized and as such, it is not possible to control the level 
of pretest risk enrichment. This is particularly concerning 
in the case of recruitment into trials, which, as noted above, 
introduces additional selection biases and may further dilute 
the risk enrichment. For example, likely because of more 
intense outreach campaigns in the community, the actual risk 
of psychosis in CHR-P samples has been declining from 29% 
(2012 (126)) to 20% (2016 (12)) worldwide. Interestingly, there 
are exceptions to this phenomenon, such as the Outreach and 
Support in South London (OASIS) CHR-P service (4), where 
transition risk has not declined over time. This is again due to the 
fact that recruitment strategies have, overall, maintained a stable 
pretest risk enrichment (127). Ultimately, innovative strategies 
TaBLE 4 | Risk enrichment impacts statistical power and sample size for experimental therapeutic trials in CHR-P samples.
Sampling Recruitment 
(pretest)(e)
Psychometric assessment 
(post-test)(e)
Total sample size excluding attrition (c)
Type of sample Risk of psychosis at 
3 years
Risk of psychosis at 3 years Risks Ratio (Risk experimental treatment/Risk 
needs-based intervention
CHR+ (a) CHR- (b) 0.5 0.6 0.7
Pretest risk in people undergoing CHR 
assessment outside randomized clinical trials
0.03(d)-0.49 0.051 0.003 2368 3942 7436
General population 0.004 0.007 < 0.001 17908 29844 56360
Neurapro trial -control arm 0.082 0.140 0.008 796 1324 2488
Pretest risk stratification
low pretest risk 0.014 0.026 0.001 4730 7880 14874
moderately low pretest risk 0.100 0.168 0.010 648 1076 2020
moderately high pretest risk 0.181 0.287 0.020 336 554 1036
high pretest risk 0.456 0.604 0.070 104 170 310
(a)LR+ = 1.82. (b)LR- = 0.09. (c)alpha = 0.05; power 90%; 2-sided; allocation ratio = 1. The sample sizes reported in the table indicate the individuals who should 
complete the trial (to estimate the baseline sample, attrition should be considered). (d)the average is 0.15 but because it depends on unstandardized idiosyncratic 
recruitment strategies, it is highly variable ranging from 3% to 49% depending on the study (5). It tends to be on the lower side when the recruitment focuses on 
children and adolescent populations, intermediate when the recruitment focuses on primary care settings and higher when the recruitment focuses on secondary care. 
In this table to allow a conservative estimate of the sample size required we use only the lower bound of 0.03. (e)Post-test probability = LR*pretest probability/[(1-pretest 
probability)+(pretest probability*LR)].
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are needed to ensure that a sufficient level of risk enrichment is 
obtained to allow adequate statistical power in CHR-P recruited 
into future trials. A possible solution could be to apply pretest 
risk stratification algorithms that have been developed and 
validated for this population using machine learning methods 
(Figure 5) (102).
For example, pretest risk estimation algorithms that are based 
on the source of referral to CHR-P clinics and ethnicity can be 
used to stratify individuals into four classes of risk enrichment: 
low risk (1% risk at 3 years, ≈21% of the CHR-P population), 
moderately low risk (10% at 3 years, ≈53% of the CHR-P 
population), moderately high (18% at 3 years, ≈21% of the 
CHR-P population), and high (46% at 3 years, ≈5% of the CHR-P 
population, Figure 5). If this simple tool is applied to individuals 
recruited for a CHR-P assessment it may be possible to control 
risk enrichment and avoid its high variability. Furthermore, 
stratification may inform the subsequent phases. For example, 
those who are at low risk are to be screened out from trial 
eligibility, a pretest risk enrichment of at least 10%—or more—
would be ensured across all participating sites (Figure 5). Under 
those circumstances, a total sample of 648 CHR-P individuals 
(ignoring attrition) would guarantee sufficient statistical power 
(90%) to test treatment effects that can halve the risk of developing 
psychosis. Alternatively, those with a moderately low pretest 
risk can be subjected to further testing to refine the prognostic 
accuracy (128). Controlling pretest risk enrichment through the 
recruitment phase is expected to mitigate the existing challenges 
and facilitate the slope of enlightenment phase (Figure 1).
Stratification and Precision Medicine
As noted above, the lack of evidence to favor specific preventive 
treatments over any others should be the basis to promote further 
research in this field, rather than to abandon it. For example, it 
is likely that a one-size-fits-all treatment approach in CHR-P 
populations is not effective and that some treatments may 
work for specific subgroups of patients. There are several lines 
of evidence to support this. First, some meta-analyses included 
in the current umbrella review report large 95% confidence 
intervals, which indicate high heterogeneity across treatments. 
Some of them may actually be effective. For example, the network 
meta-analysis exploring the effect of treatments on the prevention 
of psychosis has suggested that the integrated psychological 
intervention developed by Bechdolf et al. (22) has the largest 
effect size for reducing the risk of psychosis onset compared to 
needs-based interventions (Odds Ratio = 0.04) (30). Although 
the 95% confidence intervals included the null hypothesis, this 
treatment could be the focus of the next generation of therapeutic 
trials. An important note is that current meta-analytical evidence 
did not favor any treatment compared to each other (including 
control conditions such as needs-based-intervention). As such, 
it is possible that needs-based-intervention per se was associated 
with improved outcomes, diluting the potential comparative 
efficacy of other interventions. Another example comes from 
the failure of some randomized controlled trials, such as the 
NEURAPRO (omega-3) when tested in an unstratified CHR-P 
sample (28). This has naturally led to the suggestion that 
omega-3 might be more efficacious in those individuals who 
specifically have low levels of membrane fatty acids at baseline 
(129). This makes sense from a pathophysiological perspective—
psychosis is a heterogeneous disorder with likely many different 
neurobiological ‘paths’ and risk factors (67), which may perturb 
an individual’s neural circuitry in various (innumerable) ways 
and which ultimately presents as psychosis (107).
Table 5 provides a clinical interpretation of the evidence for 
selecting preventive interventions for CHR-P individuals.
Second, there is converging evidence indicating that the 
CHR-P group is clinically heterogeneous. For example, there is 
high heterogeneity in the level of risk for psychosis across the 
three CHR-P subgroups of the attenuated psychotic symptoms, 
brief and limited intermittent psychotic symptoms, and genetic 
risk and deterioration syndrome (12, 116, 117). In particular, 
those meeting the brief and limited intermittent psychotic 
symptoms criteria have a very high risk of developing persistent 
psychotic disorders. Recent studies also demonstrate that these 
patients are those in highest clinical need but receive inadequate 
care (130, 131). Such a heterogeneity calls for a revision of the 
CHR-P paradigm which should include clinical stratification 
across these three subgroups (10, 17). Ongoing international 
consortia such as PSYSCAN, PRONIA, and NAPLS have already 
TaBLE 5 | Clinical interpretation of the current evidence for selecting a preventive 
intervention for CHR-P individuals.
Currently, no reliable recommendation can be made regarding whether specific 
interventions (e.g. psychological interventions, medications, dietary interventions, 
needs-based interventions) are more effective compared to each other for the 
prevention of psychosis in CHR-P individuals.
Consequently, the safest approach is recommended, that is needs-based 
interventions and psychological interventions over antipsychotics, because the 
latter are not more efficacious than other options and have known side effects.
The selection of these two interventions should be based on factors such as 
the characteristics of each individual. These can include patients’ preferences 
(e.g., some patients may prefer psychological interventions over needs-based 
interventions), social circumstances (e.g. needs based interventions which include 
housing/vocational support may be suited for patients for whom these issues 
represent the presenting complaint), nature of symptoms (e.g. psychological 
interventions may be indicated for those presenting with cognitive biases in addition 
to attenuated psychotic symptoms), predicted risk (e.g. those presenting with brief 
and limited intermittent psychotic symptoms may need psychological treatments 
beyond needs-based interventions) or the local availability of each intervention.
Some suggestions can be made on the basis of differences that, even if non-
statistically significant, had at least a moderate effect size (Odds Ratio > 2.5 for 
preventing the onset of psychosis, or Cohen’s d > 0.5 for reducing symptoms).
• The most efficacious intervention for preventing psychosis onset could be 
Integrated Psychological Interventions (IPI), and the second most efficacious 
could be Cognitive Behavioral Therapy (van der Gaag protocol) combined with 
needs-based interventions.
• Omega-3 and CBT could be more efficacious than IPI for improving attenuated 
positive psychotic symptoms.
• N-methyl-d-aspartate receptor modulators could be more efficacious than 
needs-based interventions alone, CBT and family therapy for improving 
attenuated negative symptoms.
• Importantly, none of these differences reached statistical significance.
Finally, it will be essential to consult the results of new and forthcoming studies 
as they emerge. In this regard, living meta-analyses could provide new evidence 
earlier than updating a conventional meta-analysis.
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started delivering precision medicine tools for stratifying CHR-P 
individuals and may permit an individualized prediction of 
their outcomes (57, 132, 133). These consortia are adopting a 
multimodal prediction approach which is spanning clinical, 
neurocognitive, neurobiological, as well as genetic predictors 
(134) to improve the individualized prognosis of outcomes in 
this population.
Individual Participant Data Living Meta-Analyses
Another precision medicine approach that is expected to advance 
knowledge is to conduct further evidence synthesis studies such 
as individual-participant data level network meta-analyses. The 
use of individual data as opposed to aggregate-level meta-analysis 
would also allow analyzing the effect of different individual 
factors (including the CHR-P subgroups) and development of 
evidence-based prognostic algorithms to forecast the likelihood 
of treatment response at the individual subject level based on these 
factors. It is expected that these individual-participant data meta-
analyses will identify specific subgroups of CHR-P individuals 
for whom current treatments (i.e. the integrated psychological 
intervention) may already be effective. A relevant issue 
(highlighted in Table 5) is that the future publication of a single 
study with robust evidence of efficacy may significantly change 
the level of evidence for preventive interventions in psychosis. As 
indicated in Table 3 and in the section below, novel compounds 
for this patient population are under investigation, and it is thus 
expected that new results will be released over the next few years. 
This would be the ideal context to conduct living meta-analyses. 
To illustrate their methodological approach and the potential 
impact in the field we have simulated a living meta-analysis. 
The simulation showed no robust evidence to favor current 
CBT treatments for the prevention of psychosis. Prospectively 
planned living systematic reviews and meta-analyses are thus 
expected in this field. The feasibility and sustainability of living 
systematic reviews can be supported by the synergic interaction 
of human effort and machine automation (135). A recent 
empirical study has demonstrated that prospectively planned 
living network meta-analyses produced strong evidence against 
the null hypothesis more often—and earlier—than conventional 
pairwise meta-analyses (39).
Innovative Youth Mental Health Services 
and Advanced Trial Designs
Additional important factors that may support the slope of 
enlightenment are the development of youth mental health 
services and innovative trial designs. The high prevalence of 
mental health problems among young people, their negative 
impact on outcomes, as well as their significant financial and 
societal cost, emphasizes the need to improve broad mental 
health care in children and young people (136). The “No 
Health Without Mental Health” report by the UK Government 
recognized that only a life-course approach would allow 
fulfilment of such an objective, and highlighted the importance 
of the early years (137). Similarly, the “Future in Mind” report 
by NHS England highlights the pressing need (by 2020) for 
a holistic approach, including better access and support for 
front-line staff, and the adoption of innovative integrated youth 
mental health approaches which depart from the current tier 
system which is split between Child and Adolescent Mental 
Health Services and Adult Mental Health Services (138). The 
OASIS model presented above already provides integrated care 
across child and adolescent and adult mental health services for 
CHR-P individuals aged 14–35. Notably, the CHR-P services 
platform has been recently implemented nationwide in some 
countries, demonstrating scalable impact for taking care of 
children and young adults. Therefore, it may be possible to 
leverage these CHR-P templates in order to refine the next 
generation of youth-friendly mental health services which 
target the needs of adolescents and young adults experiencing 
early stages of other mental disorders, such as depression (139) 
and bipolar disorders (140, 141). Some integrated models of 
care have already capitalized on the CHR-P platform to broaden 
their horizons and target the wider mental health of children 
and young adults. In 2006, following a campaign that was led 
by leaders in mental health, the early intervention model for 
psychosis was then expanded to other diagnoses (e.g., mood, 
personality, eating, and substance use disorders) through 
the creation of Headspace in Australia (142). Headspace is a 
government-funded initiative that provides youth-friendly, 
stigma-free early intervention services in a ‘one-stop shop’ 
location to 12–25-year olds with emerging mental health and 
substance use disorders (142). Within this context, mental 
healthcare is multidisciplinary, integrated, delivered in a single 
setting and is centered on the needs of young people along with 
their families (143). The youth mental health reform achieved in 
Australia has permeated to other regions of the world, with the 
UK, Ireland, Canada, USA, Europe, and Asia adopting similar, 
culturally appropriate models (143, 144).
Youth mental health services may offer some additional clinical 
research advantages because they fully embed the clinical staging 
model for the emergence of several mental disorders (1, 145). In 
turn, this would facilitate stepped clinical care. For example, by 
adopting subsequent prognostic assessments (8) in young people 
at risk for emerging mental disorders, it may be possible to refine 
the prediction of their longitudinal outcomes while optimizing 
the logistic resources and translational impact (128). The stepped 
prognosis can be associated with stepped care, which targets the 
level of need and risk presented by each person. Adaptive clinical 
trials represent an innovative and flexible method, allowing pre-
specified modifications to the design or statistical procedures 
of an on-going trial depending on the data generated from it. 
Such adaptive design trials can boost clinical research by cutting 
costs and time, and more importantly, by adapting to the clinical 
stages of the stepped care model implemented in youth mental 
health services. The first adaptive design clinical trial, the Staged 
Treatment in Early Psychosis Study (STEP) (146), is ongoing and 
more are expected to follow.
New Experimental Therapeutics
As indicated in our latest network meta-analyses (30, 61) and 
in Table 3, innovative experimental therapeutics in CHR-P 
individuals are under development. These compounds, if 
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used along with the above strategies, are expected to advance 
knowledge in this field.
In summary, the slope of enlightenment and future 
advancements of knowledge in this field could be facilitated 
by controlling pretest risk enrichment in samples undergoing 
CHR-P assessment, stratifying CHR-P samples to allow precision 
medicine approaches, conducting Individual Participant Data 
and living meta-analyses, adopting innovative youth mental 
health services and advanced trial designs, and testing novel 
experimental therapeutics.
cONcLUSiONS
This umbrella review found no convincing evidence for 
superior efficacy of any current preventive treatment, compared 
to each—and every—other, on the risk of psychosis onset, 
acceptability of treatments, severity of attenuated positive and 
negative psychotic symptoms, depression, symptom-related 
distress, social functioning, general functioning, or quality of 
life in CHR-P individuals. Current interventional literature 
in CHR-P population has been only powered to detect large 
effect sizes for preventive treatments. Prevention of psychosis 
from a CHR-P state has been and should remain the (first 
order) primary outcome of interventional research, refined and 
complemented by other clinically meaningful outcomes. The 
stagnation of knowledge in the field should promote innovative 
and collaborative research efforts, rather than give us cause to 
abandon it. Advancements will most likely be associated with 
the ability to deconstruct the high heterogeneity of CHR-P 
populations. This would require the estimation of treatment-
specific effect sizes through individual participant data meta-
analyses, controlling risk enrichment during recruitment, and 
embedding stratification and precision medicine methods 
within new youth mental health services that can accommodate 
staged care, stepped prognosis, and advanced trial designs. 
Several experimental therapeutics studies in CHR-P individuals 
are also ongoing. The strategies which could facilitate reaching 
the plateau of knowledge in CHR-P field are summarized in 
Gartner Hype Cycle (Figure 1). We hope that these innovations 
will ultimately pave the way toward a future plateau of knowledge 
and refined preventive treatments that could result in tangible 
benefits for clinicians, researchers, and, more importantly, for 
patients and their families.
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